Patent
Antimicrobially active polypeptides
| العنوان: | Antimicrobially active polypeptides |
|---|---|
| Patent Number: | 6,310,176 |
| تاريخ النشر: | October 30, 2001 |
| Appl. No: | 09/319,730 |
| Application Filed: | August 24, 1999 |
| مستخلص: | A polypeptide selected from peptides (1) and functional derivatives and pharmaceutically acceptable salts thereof; pharmaceutical compositions containing one or more of these polypeptides; and a method for inhibiting microbial growth in animals using such polypeptides. |
| Inventors: | Barra, Donatella (Rome, ITX); Simmaco, Maurizio (Rome, ITX) |
| Assignees: | SBL Vaccin AB (Stockholm, SEX) |
| Claim: | What is claimed is |
| Claim: | 1. A polypeptide selected from the following peptides SEQ ID NOS: 1-11 |
| Claim: | F L P L I G R V L S G I L - amide |
| Claim: | L L P I V G N L L K S L L - amide |
| Claim: | L L P I L G N L L N G L L - amide |
| Claim: | L L P I V G N L L N S L L - amide |
| Claim: | V L P I I G N L L N S L L - amide |
| Claim: | F L P L I G K V L S G I L - amide |
| Claim: | F F P V I G R I L N G I L - amide |
| Claim: | L S P N L L K S L L - amide |
| Claim: | L L P N L L K S L L - amide |
| Claim: | F V Q W F S K F L G R I L - amide, and |
| Claim: | G L L S G L K K V G K H V A K N V A V S L M D S L K C K I S G D C |
| Claim: | and pharmaceutically acceptable salts of the peptides of SEQ ID NOS 1-11. |
| Claim: | 2. A therapeutic composition comprising one or more polypeptides according to claim 1, wherein the composition has antibacterial or antifungal activity. |
| Claim: | 3. An antimicrobial composition comprising one or more polypeptides according to claim 1, wherein the composition has antibacterial or antifungal activity. |
| Claim: | 4. The antimicrobial composition according to claim 3, wherein the composition has antibacterial or antifungal activity. |
| Claim: | 5. A medicament comprising one or more polypeptides according to claim 1, wherein the medicament has antimicrobial activity. |
| Claim: | 6. The medicament of claim 5, wherein said medicament further has antibacterial or antifungal activity. |
| Claim: | 7. A pharmaceutical composition comprising as an active ingredient one or more polypeptides according to claim 1 in an amount effective to inhibit microbial growth together with a pharmaceutically acceptable carrier or diluent. |
| Claim: | 8. A pharmaceutical composition according to claim 7, wherein said active ingredient is in an amount effective to inhibit bacterial or fungal activity. |
| Claim: | 9. A pharmaceutical composition according to claim 7, wherein said pharmaceutical composition is in a form for oral, intravenous, intramuscular or subcutaneous administration. |
| Claim: | 10. An isolated cDNA clone comprising the nucleic acid encoding the polypeptide sequence selected from the group consisting of SEQ ID NO: 2, 7, and 8. |
| Claim: | 11. A method for inhibiting microbial growth in animals, comprising the step of administering to an animal subject to a disorder caused by a microbial infection one or more polypeptides according to claim 1 in an antimicrobial effective amount. |
| Claim: | 12. A method for inhibiting bacterial or fungal growth in animals, comprising the step of administering to an animal subject to a disorder caused by bacterial or fungal infection one or more polypeptides according to claim 1 in an antimicrobial or antifungal effective amount. |
| Claim: | 13. A pharmaceutical composition according to claim 8, wherein said pharmaceutical composition is in a form for oral, intravenous, intramuscular or subcutaneous administration. |
| Claim: | 14. A method of inhibiting microbial growth in animals, comprising the step of administering to an animal subject suffering from a disorder caused by a microbial infection the pharmaceutical composition according to claim 7 in an antimicrobial effective amount. |
| Claim: | 15. A method according to claim 14, wherein the microbial growth is bacterial or fungal growth. |
| Claim: | 16. A method according to claim 14, wherein administering the pharmaceutical composition comprises injecting the pharmaceutical composition in a suitable amount to inhibit microbial growth. |
| Claim: | 17. A method according to claim 15, wherein administering the pharmaceutical composition comprises injecting the pharmaceutical composition in a suitable amount to inhibit bacterial or fungal growth. |
| Current U.S. Class: | 530/300; 530/300; 530/324; 530/325; 530/350; 530/326; 514/2; 514/12; 525/541; 536/232 |
| Current International Class: | C07K 500; C07K 700; A61K 3800; A61K 3702 |
| Patent References Cited: | 5447914 September 1995 Travis et al. |
| Other References: | Sequence Database Printout.* Simmaco et al., "Temporins, antimicrobial peptides from the European red frog Rana temporaria", European Journal of Biochemistry, vol. 242, pp. 788-792.* "Temporins, antimicrobial peptides from the European red frog Rana temporaria", Maurizio Simmaco et al., Eur. J. Biochem., vol. 242 (1996) pp. 788-792. "Amphibian skin: a promising resource for antimicrobial peptides", Donnatella Barra et al., TibTech, vol. 13 (Jun. 1995) pp. 205-209. "Antimicrobial Peptides from Skin Secretions of Rana esculenta", Maurizio Simmaco et al., The Journal of Biological Chemistry, vol. 269, No. 16, (Apr. 22, 1994) pp. 11956-11961. "Brevinin-1 and -2, Unique Antimicrobial Peptides from the Skin of the Frog, Rana Brevipoda Porsa", Noriyuki Morikawa et al., Biochemical and Biophysical Research Communications, vol. 189, No. 1 (Nov. 30, 1992) pp. 184-190. "Isolation and Characterization of Novel Antimicrobial Peptides, Rugosins A, B and C, from Skin of the Frog, Rana rugosa", Shintaro Suzuki et al., Biochemical and Biophysical Research Communications, vol. 212, No. 1 (Jul. 6, 1995) pp. 249-254. "Ranalexin: A Novel Antimicrobial Peptide from Bullfrog (Rana catesbeiana) Skin, Structurally Related to the Bacterial Antibiotic, Polymyxin", Douglas P. Clark et al., The Journal of Biological Chemistry, vol. 269, No. 14 (Apr. 8, 1994) pp. 10849-10855. "Antimicrobial Peptides from the Skin of a Korean Frog, Rana rugosa", Jin Mo Park et al., Biochemical and Biophysical Research Communications, vol. 205, No. 1 (Nov. 30, 1994) pp. 948-954. |
| Primary Examiner: | Carlson, Karen Cochrane |
| Assistant Examiner: | Robinson, Patricia |
| Attorney, Agent or Firm: | Burns, Doane, Swecker & Mathis, L.L.P. |
| رقم الانضمام: | edspgr.06310176 |
| قاعدة البيانات: | USPTO Patent Grants |
| الوصف غير متاح. |